Business of Biotech Podcast: Potential for Antibody CB1 Inhibitor
Obesity Tx End-Around With Skye Bioscience’s Punit Dhillon
A discussion of the merits of an antibody-based CB1 inhibitor, potential lack of neuropsychiatric side effects, and potential role of a CB1 inhibitor in the realm of weigh loss therapeutics.